Feasibility and tolerability of ophthalmic virtual reality as a medical communication tool in children and young people.

"Adnan Tufail received a portion of funding from the Department of Health’s NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital and UCL Institute of Ophthalmology, United Kingdom, and is a consultant for Heidelberg Engineering. Peter Maloca owns intellectual properties on speckle denoising. Peter Maloca and Pascal Hasler receive lecture fees from Heidelberg. Dr. Scholl is member of the Scientific Advisory Board of: Astellas Institute for Regenerative Medicine; Gensight Biologics; Ionis Pharmaceuticals, Inc.; Gyroscope Therapeutics Ltd.; Janssen Research & Development, LLC (Johnson & Johnson); and Pharma Research & Early Development (pRED) of F. Hoffmann‐La Roche Ltd; Novartis Pharma AG (CORE). Dr. Scholl is paid consultant of: Boehringer Ingelheim Pharma GmbH & Co; Gerson Lehrman Group; and Guidepoint. Dr. Scholl is member of the Data Monitoring and Safety Board/Committee of Belite Bio and ReNeuron Group Plc/Ora Inc. and member of the Steering Committee of Novo Nordisk (FOCUS trial). Dr. Scholl is co‐director of the Institute of Molecular and Clinical Ophthalmology Basel (IOB) which is constituted as a non‐profit foundation and receives funding from the University of Basel, the University Hospital Basel, Novartis, and the government of Basel‐Stadt. These arrangements have been reviewed and approved by the University of Basel (Universitätsspital Basel, USB) in accordance with its conflict of interest policies."

"Adnan Tufail received a portion of funding from the Department of Health’s NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital and UCL Institute of Ophthalmology, United Kingdom, and is a consultant for Heidelberg Engineering. Peter Maloca owns intellectual properties on speckle denoising. Peter Maloca and Pascal Hasler receive lecture fees from Heidelberg. Dr. Scholl is member of the Scientific Advisory Board of: Astellas Institute for Regenerative Medicine; Gensight Biologics; Ionis Pharmaceuticals, Inc.; Gyroscope Therapeutics Ltd.; Janssen Research & Development, LLC (Johnson & Johnson); and Pharma Research & Early Development (pRED) of F. Hoffmann‐La Roche Ltd; Novartis Pharma AG (CORE). Dr. Scholl is paid consultant of: Boehringer Ingelheim Pharma GmbH & Co; Gerson Lehrman Group; and Guidepoint. Dr. Scholl is member of the Data Monitoring and Safety Board/Committee of Belite Bio and ReNeuron Group Plc/Ora Inc. and member of the Steering Committee of Novo Nordisk (FOCUS trial). Dr. Scholl is co‐director of the Institute of Molecular and Clinical Ophthalmology Basel (IOB) which is constituted as a non‐profit foundation and receives funding from the University of Basel, the University Hospital Basel, Novartis, and the government of Basel‐Stadt. These arrangements have been reviewed and approved by the University of Basel (Universitätsspital Basel, USB) in accordance with its conflict of interest policies. Dr. Scholl is principal investigator of grants at the USB sponsored by the following entities: IVERIC bio (Ophthotech Corporation); Kinarus AG; and Novartis Pharma AG. Grants at USB are negotiated and administered by the institution (USB) which receives them on its proper accounts. Philippe C Cattin is the owner of the described method and his work has been funded by the Werner Siemens Foundation through the MIRACLE project. Others: none."